| General information | |
| ACovPid: | ACoVP100225 |
| Trivial Name: | SARS-WW-III |
| Amino Acids Sequence: | GYHLMSFPQAAPHGVVFLHVTW |
| Length: | 22 |
| C-Terminal Modification: | None |
| N-Terminal Modification: | None |
| Chemical Modification: | None |
| Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Source Description: | S2 subunit of spike (S) glycoprotein of SARS-CoV |
| Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Inhibition Value Type: | IC50 |
| Inhibitory Effect: | ~ 2 |
| Inhibitory Unit: | µM |
| Target Domain Name: | |
| Assay: | Plaque reduction assay |
| Assay Description: | For plaque reduction assays, Vero E6 cells or L2 cells were seeded at a density of 1 × 106 cells in each well of a 6-well plate 24 h (h) prior to infection. Approximately 50 plaque forming units (PFU) of either SARS-CoV strain Urbani or MHV were pre-incubated with peptide or without peptide (diluent control) in serum-free MEM (SARS-CoV) or serum-free DMEM (MHV) for 1 h at 37 °C. Vero E6 or L2 cells were then infected with (1) peptide- or vehicle-treated SARS-CoV inoculum or (2) peptide- or vehicle-treated MHV inoculum, respectively. After 1 h adsorption, the inoculum was removed, cells were washed twice with 1× phosphate buffered saline (PBS), and then overlaid with 10% FBS/MEM or 10% FBS/DMEM, both containing 0.5% Noble Agar (Sigma, Rockland, ME). L2 cells were fixed 2 days p.i. with 3.7% formalin for 2 h at room temperature and then stained with 1× crystal violet to visualize plaques. Vero E6 cells were stained with neutral red 3 days p.i. and plaque numbers were determined 24 h later. |
| Anti-CoV activity in vivo: | |
| Reference: | 16616792 |
| Comment: | |
| 3D structure: | |
| Structure Experiment Verified: | NO |
| Similar Peptides: | |